Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on LTR Pharma.
RELATED STOCKHEAD STORIES
Health & Biotech
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
News
ASX August Winners: The 50 best stocks in a volatile month for markets
Stockhead TV
Long Shortz with LTR Pharma: Erectile dysfunction help just a spray away
Health & Biotech
ASX Health Stocks: Lift off for LTR Pharma’s ED therapy under TGA scheme
News
Closing Bell: ASX climbs as Tech takes charge; CBA, AGL gain on earnings, LiveHire doubles
Health & Biotech
LTP enters deal with Aptar Pharma to develop Spontan nasal spray
News
Rise and Shine: Everything you need to know before the ASX opens
News
ASX Small Caps Lunch Wrap: Earnings in full swing as CSL tumbles, Temple and Webster skyrockets 27pc
Health & Biotech
ASX Health Stocks: Anteris plans for US IPO and listing on Nasdaq
Health & Biotech
ASX Health Stocks: Big tick for Cynata’s stem-cell therapy
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
News
Closing Bell: ASX, Nikkei fight back; RBA refuses to budge on interest rates
Stockhead TV
Break it Down: LTR Pharma prescribes ED spray under TGA scheme
Health & Biotech
Patients uplifted by LTR Pharma’s ED treatment Spontan under TGA scheme
Health & Biotech
ASX Health Stocks: PYC’s visionary drug shows promise; Spontan ED spray available under TGA program
Health & Biotech
ScoPo’s Powerplays: ASX health stocks up in ‘fairly lacklustre week’
Health & Biotech
